within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AG07_Begelomab;
model Begelomab 
   extends Pharmacolibrary.Drugs.ATC.L.L04AG07;

  annotation(Documentation(
    info ="<html><body><p>Begelomab is a monoclonal antibody directed against CD26, developed for immunosuppression in transplantation, particularly in steroid-refractory acute graft-versus-host disease (aGVHD). It has received orphan drug designation but is not widely approved or in routine use.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic studies are available for begelomab in humans in the scientific literature as of June 2024. Estimated PK parameters for monoclonal antibodies of similar class are provided.</p><h4>References</h4><ol></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Begelomab;
